I'd like to respond to that briefly. Our members have been very actively involved in discussions with Health Canada around the progressive licensing framework and the life-cycle approach.
Regarding your specific question around marketing approvals with conditions, we are examining that quite closely as well. We would just add the caveat that discussions around that type of framework need to also occur with the provinces, because our members who manufacture biologic products are somewhat concerned that anything less than a full market approval by Health Canada will inhibit the ability of provinces to make positive decisions regarding reimbursement of those products. We encourage very careful collaboration, so that provinces definitely understand what those notices of compliance with conditions actually mean.